Actionable news
All posts from Actionable news
Actionable news in EXAS: EXACT Sciences Corporation,

Colon Cancer Alliance: U.S. Preventive Services Task Force Recommendations Same tests recommended: expect the same outcome - stagnant screening rates

First, USPSTF provides inclusion in the guideline for FIT-DNA, available as Cologuard, in their draft only as an alternative screening test that may be useful in certain clinical situations. Cologuard is a screening test that the U.S. Food and Drug Administration (FDA) approved in 2014. The Centers for Medicare and Medicaid Services (CMS) also approved FIT-DNA for Medicare reimbursement with an interval of every three years.

In this guideline, the USPSTF continues to endorse only the traditional stool-based test (FIT), which has never been approved by the FDA but is simply "cleared" based on its ability to detect blood, not its ability to detect colon cancer. USPSTF notes that the FIT-DNA test is significantly better than FIT at finding colon cancer but may be more likely to have a false positive, meaning that the test may report a positive result for someone who does not have colon cancer. What they failed to acknowledge is that the test can also detect significant...